Clinical Trial Update: Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis

View source ↗

Summary

A double-blind clinical trial evaluating WBI-1001 cream for psoriasis has completed. The study is sponsored by Welichem Biotech Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• WBI-1001 Cream (WBI-1001)

Snippet

Sponsor: Welichem Biotech Inc. | Conditions: Psoriasis | Status: COMPLETED